Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

This article was originally published in The Pink Sheet Daily

Executive Summary

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

You may also be interested in...



Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test

Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.

Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test

Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.

With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor

Takeda/Millennium’s oral weekly proteasome inhibitor MLN9708 looked effective with a mild neuropathy profile in a new myeloma study presented at the American Society of Hematology meeting, and Takeda has committed to large Phase III trials. There’s no time to lose – mid-stage studies presented for Onyx’ rival Kyprolis, currently approved for relapsed myeloma, support moving that drug to the frontline.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel